Phenylbutanoic Acid

Phenylbutanoic Acid

SCHEMBL406962

O=C(CCCc1ccccc1)OCC(O)CO.O=C(O)CCCc1ccccc1.O=C(O)CCCc1ccccc1

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.62
ADRB1 P08588 1/20 0.62
ADRB3 P13945 1/20 0.62
LPAR1 Q92633 5/20 0.58
HDAC3 O15379 1/20 0.58
MAPK1 P28482 1/20 0.58
ADRA1A P35348 1/20 0.58
HDAC4 P56524 1/20 0.58
SLC6A3 Q01959 1/20 0.58
HDAC1 Q13547 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
HDAC7 Q8WUI4 1/20 0.58
HDAC2 Q92769 1/20 0.58
HDAC10 Q969S8 1/20 0.58
HDAC11 Q96DB2 1/20 0.58
HDAC8 Q9BY41 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
HDAC9 Q9UKV0 1/20 0.58
HDAC5 Q9UQL6 1/20 0.58
MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1983179 0.96 ADRB2 (0.66) ADRB2ADRB1ADRB3LPAR1HDAC3
SCHEMBL11293636 0.90 LPAR1 (0.70) ADRB2ADRB1ADRB3LPAR1MAPT
SCHEMBL29028798 0.90 LPAR1 (0.70) ADRB2ADRB1ADRB3LPAR1MAPT
SCHEMBL9463643 0.88 LPAR1 (0.71) ADRB2ADRB1ADRB3LPAR1HDAC3
Phenylbutanoic Acid SCHEMBL28794522 0.88 HDAC3 (0.61) ADRB2ADRB1ADRB3LPAR1HDAC3
Phenylbutanoic Acid SCHEMBL15285203 0.85 HDAC1 (0.75) HDAC3MAPK1ADRA1AHDAC4SLC6A3
SCHEMBL11855276 0.82 ADRB2 (0.52) ADRB2ADRB1ADRB3LPAR1KDM4E
SCHEMBL27457920 0.82 KDM4E (0.64) LPAR1MAPTKDM4EDUSP3MEN1
SCHEMBL270754 0.82 LMNA (0.69) LPAR1MAPTKDM4EDUSP3MEN1
SCHEMBL8427652 0.81 ADRB2 (0.55) ADRB2ADRB1ADRB3LPAR1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11786494-B2 Methods of modulation of branched chain acids and uses thereof BAYLOR COLLEGE OF MEDICINE (US) 2023-10-17 US claimed
US-20200405678-A1 METHODS OF TREATING UREA CYCLE DISORDERS HORIZON THERAPEUTICS, LLC 2020-12-31 US claimed
EP-3222275-B1 METHODS OF THERAPEUTIC MONITORING OF PHENYLACETIC ACID PRODRUGS IMMEDICA PHARMA AB (SE) 2020-06-24 EP claimed
US-20200147016-A1 METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF ACER THERAPEUTICS INC. 2020-05-14 US claimed
US-10617665-B2 Methods of therapeutic monitoring of nitrogen scavenging drugs HORIZON THERAPEUTICS, LLC (US) 2020-04-14 US claimed
EP-2986325-B1 METHODS OF TREATING UREA CYCLE DISORDERS IMMEDICA PHARMA AB (SE) 2019-06-26 EP claimed
US-20190151268-A1 METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF ACER THERAPEUTICS INC. 2019-05-23 US claimed
US-20190125713-A1 METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS HORIZON THERAPEUTICS U.S. HOLDING LLC 2019-05-02 US claimed
US-10183002-B2 Methods of therapeutic monitoring of nitrogen scavenging drugs HORIZON THERAPEUTICS, LLC (US) 2019-01-22 US claimed
US-10183006-B2 Methods of therapeutic monitoring of nitrogen scavenging drugs HORIZON THERAPEUTICS, LLC (US) 2019-01-22 US claimed
EP-2760479-A2 METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS Hyperion Therapeutics, Inc. (US) 2014-08-06 EP claimed
WO-2014081977-A1 METHODS OF ADMINISTERING AND EVALUATING NITROGEN SCAVENGING DRUGS FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY SCHARSCHMIDT BRUCE (US) 2014-05-30 WO claimed
US-20140142186-A1 METHODS OF ADMINISTERING AND EVALUATING NITROGEN SCAVENGING DRUGS FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY HORIZON THERAPEUTICS U.S. HOLDING LLC 2014-05-22 US claimed
US-8642012-B2 Methods of treatment using ammonia-scavenging drugs HYPERION THERAPEUTICS, INC. (US) 2014-02-04 US claimed
US-20130210914-A1 METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS HYPERION THERAPEUTICS, INC. (US) 2013-08-15 US claimed
WO-2013079205-A1 LOW DOSE THERAPEUTIC USE OF GLYCERYL TRI-(4-PHENYLBUTYRATE) LUNAMED AG (CH) 2013-06-06 WO claimed
EP-2599482-A1 Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate) Lunamed AG (CH) 2013-06-05 EP claimed
US-20130085179-A1 METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS HORIZON THERAPEUTICS U.S. HOLDING LLC 2013-04-04 US claimed
WO-2013048558-A2 METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS HYPERION THERAPEUTICS, INC. (US) 2013-04-04 WO claimed
US-8404215-B1 Methods of therapeutic monitoring of nitrogen scavenging HYPERION THERAPEUTICS, INC. (US) 2013-03-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190151268-A1 METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF OAT, ABAT, BCKDK ADRB2 2725/4885ADRB1 1772/4885ADRB3 1121/4885
US-20200405678-A1 METHODS OF TREATING UREA CYCLE DISORDERS UROD, SLC14A1, UGDH ADRB2 3988/4885ADRB1 3660/4885ADRB3 3991/4885
US-20130085179-A1 METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS OAT, NPR1, CPS1 ADRB2 1778/4885ADRB1 1837/4885ADRB3 1956/4885
US-20190125713-A1 METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS OAT, NPR1, CPS1 ADRB2 1778/4885ADRB1 1837/4885ADRB3 1956/4885
US-10617665-B2 Methods of therapeutic monitoring of nitrogen scavenging drugs OAT, NPR1, CPS1 ADRB2 1778/4885ADRB1 1837/4885ADRB3 1956/4885
US-10183002-B2 Methods of therapeutic monitoring of nitrogen scavenging drugs OAT, NPR1, CPS1 ADRB2 1778/4885ADRB1 1837/4885ADRB3 1956/4885
US-10183006-B2 Methods of therapeutic monitoring of nitrogen scavenging drugs OAT, NPR1, CPS1 ADRB2 1778/4885ADRB1 1837/4885ADRB3 1956/4885
US-20130210914-A1 METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS OAT, NPR1, CPS1 ADRB2 1778/4885ADRB1 1837/4885ADRB3 1956/4885
US-20200147016-A1 METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF OAT, ABAT, BCKDK ADRB2 2725/4885ADRB1 1772/4885ADRB3 1121/4885
US-11786494-B2 Methods of modulation of branched chain acids and uses thereof OAT, ABAT, BCKDK ADRB2 2725/4885ADRB1 1772/4885ADRB3 1121/4885
US-20140142186-A1 METHODS OF ADMINISTERING AND EVALUATING NITROGEN SCAVENGING DRUGS FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY OAT, OTC, GLS2 ADRB2 2022/4885ADRB1 2184/4885ADRB3 1829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.